Japan's Olympus Corporation Backs Israeli Medical Company Medi-Tate
Olympus agreed to invest $20 million in Medi-Tate, which develops medical devices to relieve symptoms of benign prostate enlargement
Medi-Tate develops medical devices to relieve symptoms of benign prostate hyperplasia (BPH), or prostate enlargement. As part of the deal, Olympus will gain exclusive rights to market Medi-Tate’s product in several undisclosed countries. Olympus will retain the right to buy all remaining Medi-Tate stock, pending Medi-Tate’s ability to meet certain milestones, Xenia said.